Metraipolis › archive › dc_d660e8f2dd58
OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma… — Europe PMC PMID:42471483
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42471483
- DOI
- 10.1038/s41416-[numero omesso]-z
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T04:21:30.039Z
- SHA-256 of the archived text
e5c2e2e538f841e2def2d6dade15e9b8cfaf2ffb99bbfe3e2cc64e473b42d790- Stable URL of this page
https://metraipolis.com/documento/dc_d660e8f2dd58
How to cite
OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma… — Europe PMC PMID:42471483 — Europe PMC (en), https://europepmc.org/article/MED/42471483 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d660e8f2dd58 (Metraipolis archive dc_d660e8f2dd58, sha256 e5c2e2e538f841e2def2d6dade15e9b8cfaf2ffb99bbfe3e2cc64e473b42d790)
BibTeX
@misc{dcd660e8f2dd58,
title = {OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma… — Europe PMC PMID:42471483},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42471483},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d660e8f2dd58; sha256 e5c2e2e538f841e2def2d6dade15e9b8cfaf2ffb99bbfe3e2cc64e473b42d790},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42471483. Agents can read the archived copy with the MCP tool read_document.